Evidence map›Paper›PMID 39918316›Full record

ArticleAntimicrobial agents and chemotherapy2025

Evaluation of two gradient diffusion tests to determine susceptibility to aztreonam and ceftazidime-avibactam in combination.

Ayesha Khan, Carmila Manuel, Richard Maynard, Romney M Humphries

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. ComparativeAntimicrobial agents and chemotherapy · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ayesha KhanPathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID 0000-0002-0489-0712
Carmila ManuelPathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Richard MaynardPathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Romney M HumphriesPathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID 0000-0002-6568-156X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The combination of aztreonam and ceftazidime-avibactam (ATM-CZA) is a last resort regimen against recalcitrant infections caused by metallo-β-lactamase (MBL)-producing organisms. Susceptibility testing is warranted due to emerging resistance to the combination, but there are no widely implemented methods for use in clinical laboratories. Here, we used a cohort of 100 Enterobacterales

Indexed as

Anti-Bacterial AgentsAzabicyclo CompoundsAztreonamCeftazidimebeta-LactamasesDrug CombinationsDrug Resistance, Multiple, BacterialEnterobacteriaceaeHumansMicrobial Sensitivity TestsPseudomonas aeruginosaStenotrophomonas maltophiliaAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsAztreonambeta-LactamasesCeftazidimeDrug Combinationsantibiotic resistanceantimicrobial agentsantimicrobial combinationsdiagnosticsEnterobacteriaceaemetalloenzymesmultidrug resistancePseudomonas aeruginosaStenotrophomonassusceptibility testing

Identifiers

PMID39918316
PMCPMC11881574

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.